Key result
The FDA utilizes various pathways for drug and device approval and post-market surveillance, which directly impact the evidence generated and available for cardiovascular patient care.
Answers are grounded in this paper and cite their sources.
Understanding FDA approval and surveillance pathways is crucial for clinicians to interpret the evidence supporting cardiovascular drugs and devices.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ross et al. (2015) conducted a review in Cardiovascular Medicine. FDA regulatory policies was evaluated. The FDA utilizes various pathways for drug and device approval and post-market surveillance, which directly impact the evidence generated and available for cardiovascular patient care.
Synapse has enriched 10 related papers. Consider them for comparative context: